Trung Huynh
Stock Analyst at UBS
(4.74)
# 140
Out of 5,113 analysts
57
Total ratings
69.23%
Success rate
26.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $105 → $130 | $107.40 | +21.04% | 4 | Jan 7, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $762.65 | -13.46% | 5 | Nov 7, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $895 → $1,080 | $1,062.75 | +1.62% | 10 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $159.72 | +39.62% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.53 | +1,533.99% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $349.69 | -9.35% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $26.57 | +43.02% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $25.88 | -3.40% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $54.60 | -1.10% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $2.95 | +137.29% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $8.88 | +46.40% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $221.49 | -20.99% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $220.77 | -23.00% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.20 | - | 1 | Mar 23, 2021 |
Merck & Co.
Jan 7, 2026
Maintains: Buy
Price Target: $105 → $130
Current: $107.40
Upside: +21.04%
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $762.65
Upside: -13.46%
Eli Lilly and Company
Nov 7, 2025
Maintains: Buy
Price Target: $895 → $1,080
Current: $1,062.75
Upside: +1.62%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $159.72
Upside: +39.62%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.53
Upside: +1,533.99%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $349.69
Upside: -9.35%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $26.57
Upside: +43.02%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $25.88
Upside: -3.40%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $54.60
Upside: -1.10%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.95
Upside: +137.29%
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $8.88
Upside: +46.40%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $221.49
Upside: -20.99%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $220.77
Upside: -23.00%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $9.20
Upside: -